BRTX — Biorestorative Therapies Share Price
0.000.00%
Last trade - 00:00- $11.63m
- $2.53m
- $0.40m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.9 | ||
| Price to Tang. Book | 2.1 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 29.75 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -199.41% | ||
| Return on Equity | -117.32% | ||
| Operating Margin | -3133.88% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 0.08 | 0.05 | 0.12 | 0.15 | 0.4 | 1.25 | 2 | 25.27% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
BioRestorative Therapies, Inc. is engaged in developing therapeutic products using cell and tissue protocols, primarily involving adult stem cells. The Company has two core programs that relate to the treatment of disc/spine disease and metabolic disorders. Its lead cell therapy candidate, BRTX-100, is a product formulated from autologous (or a person's own) cultured mesenchymal stem cells collected from the patient's bone marrow. It has commenced a Phase II clinical trial using BRTX-100 to treat chronic lower back pain arising from degenerative disc disease. The Company is engaged in developing a cell-based therapy candidate, ThermoStem Program, which targets obesity and metabolic disorders using brown adipose (fat) derived stem cells to generate brown adipose tissue (BAT). It has also licensed an investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. It also operates a commercial biocosmeceutical platform.
Directors
- Last Annual
- December 31st, 2024
- Last Interim
- March 31st, 2025
- Incorporated
- December 23rd, 2022
- Public Since
- July 11th, 2001
- No. of Shareholders
- 530
- No. of Employees
- 11
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 7,504,780
- Address
- 40 MARCUS DRIVE, MELVILLE, 11747
- Web
- https://www.biorestorative.com/
- Phone
- +1 6317608100
- Contact
- Mandy Clyde
- Auditors
- Marcum LLP
Upcoming Events for BRTX
BioRestorative Therapies Inc Annual Shareholders Meeting
Q3 2025 BioRestorative Therapies Inc Earnings Release
Similar to BRTX
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
Aclarion
NASDAQ Capital Market
Acurx Pharmaceuticals
NASDAQ Capital Market
FAQ
What is the Biorestorative Therapies share price?
As of Today at 19:36 UTC, shares in Biorestorative Therapies are trading at $1.55. This share price information is delayed by 15 minutes.
How has the Biorestorative Therapies share price performed this year?
Shares in Biorestorative Therapies last closed at $1.55 and the price had moved by -17.11% over the past 365 days. In terms of relative price strength the Biorestorative Therapies share price has underperformed the S&P500 Index by -25.9% over the past year.
What are the analyst and broker recommendations for Biorestorative Therapies?
The overall consensus recommendation for Biorestorative Therapies is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Biorestorative Therapies dividend yield?
Biorestorative Therapies does not currently pay a dividend.
Does Biorestorative Therapies pay a dividend?
Biorestorative Therapies does not currently pay a dividend.
When does Biorestorative Therapies next pay dividends?
Biorestorative Therapies does not currently pay a dividend.
How do I buy Biorestorative Therapies shares?
To buy shares in Biorestorative Therapies you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Biorestorative Therapies?
As of the previous close price of $1.55, shares in Biorestorative Therapies had a market capitalisation of $11.63m.
Where are Biorestorative Therapies shares listed?
Here are the trading details for Biorestorative Therapies:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: BRTX
What kind of share is Biorestorative Therapies?
Based on an overall assessment of its quality, value and momentum Biorestorative Therapies is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Biorestorative Therapies share price forecast for 2025?
The analyst consensus target price for shares in Biorestorative Therapies is $13.00. That is 738.71% above the last closing price of $1.55.
Analysts covering Biorestorative Therapies currently have a consensus Earnings Per Share (EPS) forecast of -$1.60 for the next financial year.
Find out moreWhat is the trend in the Biorestorative Therapies share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Biorestorative Therapies. Over the past six months, its share price has underperformed the S&P500 Index by -0.85%.
As of the last closing price of $1.55, shares in Biorestorative Therapies were trading -10.34% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Biorestorative Therapies PE Ratio?
The Biorestorative Therapies PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.55.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Biorestorative Therapies?
We do not have data on Biorestorative Therapies' directors